Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Abi Williams"'
Autor:
Gregor Jemec, Nana Overgaard Herschend, Helle Doré Hansen, Amy Findley, Abi Williams, Kate Sully, Tonny Karlsmark, Zenia Størling
Publikováno v:
PeerJ, Vol 11, p e16685 (2023)
Background Peristomal skin complications (PSCs) pose a major challenge for people living with an ostomy. To avoid severe PSCs, it is important that people with an ostomy check their peristomal skin condition on a regular basis and seek professional h
Externí odkaz:
https://doaj.org/article/d38a26dcac1c444ab197f56eb677af2c
Publikováno v:
Quality of Life Research. 31:3433-3445
Quality of life research often collects daily information and averages this over a week, producing a summary score. When data are missing, arbitrary rules (such as requiring at least 4/7 observations) are used to determine whether a patient's summary
Autor:
Pip Griffiths, Joel Sims, Abi Williams, Nicola Williamson, David Cella, Elaine Brohan, Kim Cocks
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.
Treatment benefit as assessed using clinical outcome assessments (COAs), is a key endpoint in many clinical trials at both the individual and group level. Anchor-based methods can aid interpretation of COA change scores beyond statistical significanc
Autor:
Pip Griffiths, Joel Sims, Abi Williams, Nicola Williamson, David Cella, Elaine Brohan, Kim Cocks
Publikováno v:
Quality of Life Research. 32:1265-1265
PurposeQuality of life research often collects daily information and averages this over a week, producing a summary score. When data are missing, arbitrary rules (such as requiring at least 4/7 observations) are used to determine whether a patient’
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03d0d77901fa252d60d016232f1b73a7
https://doi.org/10.21203/rs.3.rs-799794/v1
https://doi.org/10.21203/rs.3.rs-799794/v1
Autor:
Philip Griffiths, Joel Sims, Abi Williams, Nicola Williamson, David Cella, Elaine Brohan, Kim Cocks
Purpose: Treatment benefit as assessed using clinical outcome assessments (COAs), is a key endpoint in many clinical trials at both the individual and group level. Anchor-based methods can aid interpretation of COA change scores beyond statistical si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4607c6847a056dad09509de1d9fae143
https://doi.org/10.21203/rs.3.rs-384605/v1
https://doi.org/10.21203/rs.3.rs-384605/v1
Autor:
David Cella, Melissa Hamilton, Steven I. Blum, Cristina Ivanescu, Abi Williams, Flavia Ejzykowicz, Robert J. Motzer
Publikováno v:
Journal of Clinical Oncology. 40:4502-4502
4502 Background: In CM 214, when compared to sunitinib (S), nivolumab plus ipilimumab (N+I) was associated with both clinical benefit and improved HRQoL as first-line treatment for intermediate/poor (I/P)-risk patients (pts). This analysis investigat
Autor:
Randy D. Gascoyne, Abi Williams, Merry Zhai, David Scott, David Belada, Thomas E. Witzig, Umberto Vitolo, Julia Braverman, Kim Cocks, Sandra Margunato-Debay, Gerardo Musuraca, Annalisa Chiappella, Grzegorz S. Nowakowski, Francesco Piazza, Muhit Ozcan, Carlo Visco, Kazuhito Yamamoto, Michael Greenwood, Myron S. Czuczman, Juan Miguel Bergua Burgues, Wojciech Jurczak
Publikováno v:
Blood. 134:3475-3475
Introduction: The phase 3 international, randomized, double-blind ROBUST clinical trial (NCT02285062) compared progression-free survival between patients with previously untreated ABC-type DLBCL treated with placebo plus rituximab, cyclophosphamide,